Epitope mapping of botulinum neurotoxins light chains
- PMID: 22922018
- PMCID: PMC3477267
- DOI: 10.1016/j.toxicon.2012.08.002
Epitope mapping of botulinum neurotoxins light chains
Abstract
Botulinum neurotoxins (BoNTs) are listed among the most potent biothreat agents. Simultaneously, two out of seven known serotypes of these toxins are used in medicine and cosmetics. This situation calls for development of detailed epitope maps of these toxins. Such maps will help to develop new ways for decreasing damage caused by these toxins if they were to be used as weapons while retaining the therapeutic effect of these toxins used as medicine. Here, we used a library of random fragments of DNA encoding the catalytic domain of botulinum neurotoxin serotype A to identify short epitope-forming sequences. We demonstrated that knowledge of such sequences in a BoNT of one serotype can be used for identification of epitope-forming sequences in other serotypes of BoNTs. We also demonstrated a serodiagnostic value of identified sequences and their ability to retain epitope-specific structures and trigger production of corresponding antibodies, even when they are transferred into a background of a completely alien carrier protein.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures





Similar articles
-
Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).PLoS One. 2009;4(3):e4924. doi: 10.1371/journal.pone.0004924. Epub 2009 Mar 17. PLoS One. 2009. PMID: 19290051 Free PMC article.
-
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.J Mol Biol. 2007 Jan 5;365(1):196-210. doi: 10.1016/j.jmb.2006.09.084. Epub 2006 Oct 3. J Mol Biol. 2007. PMID: 17059824 Free PMC article.
-
Recombinant proteins that trigger production of antibodies recognizing botulinum neurotoxin while not possessing sequences of this toxin.Toxicon. 2013 Jun 1;67:63-70. doi: 10.1016/j.toxicon.2013.02.011. Epub 2013 Mar 13. Toxicon. 2013. PMID: 23499926
-
Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.Immunol Invest. 1997 Jun;26(4):491-504. doi: 10.3109/08820139709022704. Immunol Invest. 1997. PMID: 9246568
-
Botulinum neurotoxins: new questions arising from structural biology.Trends Biochem Sci. 2014 Nov;39(11):517-26. doi: 10.1016/j.tibs.2014.08.009. Epub 2014 Oct 1. Trends Biochem Sci. 2014. PMID: 25282537 Review.
Cited by
-
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9. MAbs. 2014. PMID: 24492304 Free PMC article.
References
-
- Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002;20:1640–1648. - PubMed
-
- Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68–84. - PubMed
-
- Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. J Protein Chem. 1996;15:691–700. - PubMed
-
- Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011;216:782–792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical